A Discussion On: Third Party Insurance for Psychedelic Assisted Therapy
PharmAla Biotech Investors Webinar
MDMA: Real World Efficacy Explored
FDA: Guidance | A Discussion On Psychedelic Regulations Globally
Optimizing Clinical Trial Design and The State of the Market
'Cortexa' explained. A Discussion on PharmAla Biotech and Vitura Health Limited Recent JV
Psychedelics Today: Manufacturing MDMA and Why Creating MDMA Analogs Is So Important
The Dales Report - Pharmala Stock Succeeds Through Tough Markets
Changes Announced By The TGA & What It Means For Psychedelics Webinar
PharmAla Biotech | Planning Psychedelic Trials & Navigating the Import/Export Process Webinar
PharmAla Biotech Supports Decision to Decriminalize Possession of MDMA in British Columbia
PharmAla Biotech signs supply deal with Global Wellness Strategies to provide MDMA for trial
Psychedelics 101 | February 8, 2022
Rick Doblin, Exec. Director, MAPS & Nick Kadysh, President & CEO, PharmAla Biotech | MDMA Conference

Press Releases

CEO Letter To Shareholders

Posted: Jun 06, 2024

PharmAla CEO Nick Kadysh Pens Op-ed: Mental Health in Crisis, MDMA May Be the Prescription

Posted: May 23, 2024

PharmAla Launches Prescriber’s Portal for Medical Professionals Focused on MDMA Therapy

Posted: May 03, 2024

PharmAla Closes Private Placement and Concurrent Debt Settlement

Posted: Apr 19, 2024

Cortexa Commences Manufacturing GMP LaNeo™ MDMA In Australia

Posted: Apr 05, 2024

Patent Allowance Granted for ALA-002 Composition by US Patent and Trademark Office

Posted: Mar 26, 2024

PharmAla Biotech Signs Sale Agreement with Numinus

Posted: Mar 26, 2024

Patent Allowance Granted for P-1 Molecule by US Patent and Trademark Office

Posted: Mar 20, 2024

Cortexa Leads the World in First Supply of Psilocybin Under the TGA’S Authorized Prescriber Scheme

Posted: Mar 18, 2024

PharmAla Announces Voting Results of Annual General and Special Meeting of Shareholders and Provides Corporate Update

Posted: Mar 08, 2024

PharmAla named an Intellectual Property Ontario Client

Posted: Feb 22, 2024

PharmAla Data to be Published in ACS Chemical Neuroscience

Posted: Feb 20, 2024

PharmAla and Red Light Holland to Collaborate on Medical Psilocybin Development

Posted: Feb 09, 2024

PharmAla Biotech Annual General Meeting Materials

Posted: Feb 06, 2024

PharmAla releases Q1 Interim Financial Statement and Business Update

Posted: Jan 31, 2024

PharmAla granted a Controlled Drugs & Substances Dealer’s License by Health Canada

Posted: Jan 25, 2024

PharmAla receives new “MDXXF” ticker from FINRA for OTCQB Listing

Posted: Jan 24, 2024

PharmAla-1 Molecule Receives US Patent Prosecution Highway Acceptance

Posted: Jan 08, 2024

PharmAla Files Audited Financials for Year Ending August 31, 2023

Posted: Dec 29, 2023

PharmAla Biotech and Filament Health Announce Release of Second Batch of GMP MDMA Capsules

Posted: Nov 15, 2023

World’s First Observational Trial to Assess Real-World Efficacy of MDMA Treatment

Posted: Nov 09, 2023

PharmAla Partners with Clariti Strategic Advisors™

Posted: Nov 08, 2023

PharmAla Completes Historic First Shipment of MDMA and Psilocybin to Cortexa

Posted: Nov 07, 2023

PharmAla Receives First Office Action for PharmAla-1 PCT Filing

Posted: Sept 25, 2023

CEO Letter to Shareholders

Posted: Sept 11, 2023

PharmAla Begins Trading on OTCQB

Posted: Sept 06, 2023

PharmAla Ships MDMA to Mind Medicine Australia and Orygen Institute

Posted: Aug 10, 2023

PharmAla Files Patent for Novel MDXX Molecule PharmAla-1

Posted: Jul 31, 2023

PharmAla Received Guidance on ALA-002 from MHRA; Launches Clinical Program with University of Sydney

Posted: Jul 20, 2023

Cortexa Makes First Drug Order for Australian Commercial Market

Posted: Jul 04, 2023

Offering Document under the Listed Issuer Financing Exemption

Posted: Jun 13, 2023

PharmAla Biotech announces Non-Brokered Private Placement Offering of up to an Aggregate of $5,000,000

Posted: Jun 12, 2023

USFDA Approves LaNeo MDMA for Clinical Trial Use in the United States

Posted: Jun 12, 2023

PharmAla Awarded Research Grant by Ontario Centre for Innovation

Posted: Jun 09, 2023

PharmAla Biotech and Shaman Pharma Granted First Ever Special Access Program Authorization for MDMA

Posted: May 16, 2023

PharmAla Biotech to form Australian Psychedelics Joint Venture with Vitura Health

Posted: May 01, 2023

PharmAla Biotech to supply Incannex with GMP LaNeo MDMA and Psilocybin

Posted: Apr 25, 2023

PharmAla Biotech to supply Clinical Psychedelic Lab at Monash University Clinical Trial with LaNeo MDMA

Posted: Apr 20, 2023

PharmAla Biotech and Filament Health Announce Release of GMP MDMA Capsules

Posted: Apr 11, 2023

PharmAla Biotech named Exclusive MDMA Supply Partner to Awakn Life Sciences

Posted: Mar 01, 2023

PharmAla Biotech Completes Annual General Meeting

Posted: Feb 28, 2023

CEO Letter to Shareholders

Posted: Feb 28, 2023

Patent Application Published for PharmAla Biotech’s MDMA Analogs

Posted: Feb 23, 2023

PharmAla Biotech closes purchase order with Emyria Ltd., completes filing of “LaNeo” trademark in Australia

Posted: Feb 14, 2023

Australia Allows Prescription of MDMA and Psilocybin in Groundbreaking Regulatory Change

Posted: Feb 03, 2023

PharmAla Biotech granted an Export Permit for 300 grams of LaNeo™ MDMA

Posted: Jan 24, 2023

PharmAla Completes Pre-IND Meeting with FDA, to present at KCSA Virtual Investor Conference

Posted: Dec 13, 2022

Mindset Pharma and PharmAla Biotech Enter into Exclusive Sales Agreement

Posted: Nov 16, 2022

PharmAla Submits Pre-IND Dossier for Novel MDMA Analog to FDA

Posted: Nov 02, 2022

PharmAla appoints Dr. Leah Mayo to Scientific Advisory Board

Posted: Oct 13, 2022

PharmAla Contracts with Clerkenwell to bring safer MDMA analogue to US, UK

Posted: Oct 11, 2022

PharmAla Biotech ready to assist Alberta Government with Clinical MDMA supply

Posted: Oct 06, 2022

PharmAla Biotech to supply University of California Clinical Trial with LaNeo™ MDMA

Posted: Oct 05, 2022

PharmAla Biotech to supply University of Sydney Clinical Trial with LaNeo™️ MDMA

Posted: Aug 31, 2022

PharmAla Biotech completes filing of patent application for 6 MDMA analogs

Posted: Aug 29, 2022

PharmAla Biotech to supply Major Australian Research Institute with LaNeo™ MDMA for Phase 3 Clinical Trial

Posted: Aug 22, 2022

PharmAla Biotech First Publicly Traded Company to Produce GMP MDMA

Posted: Aug 15, 2022

PharmAla Biotech Applauds Sen. Cory Booker and Sen. Rand Paul's Bill to Include MDMA in "Right-to-Try" Legislation

Posted: Aug 04, 2022

PharmAla Biotech appoints Kevin Roy to its Board of Directors

Posted: Jul 04, 2022

PharmAla Biotech Registers Trademark for MDMA

Posted: Jun 24, 2022

PharmAla Biotech Supports Decision to Decriminalize Possession of MDMA in British Columbia

Posted: Jun 02, 2022

Psychedelics Canada Announces The Launch Of The First National Trade Association For Legal Psychedelics Companies

Posted: May 27, 2022

PharmAla Biotech & SABI Mind Announce MDMA Supply Agreement

Posted: May 19, 2022

PharmAla Biotech Expands MDMA Distribution with CCrest Labs

Posted: May 10, 2022

PharmAla Biotech to supply Mind Medicine Australia with GMP MDMA for Clinical Trial

Posted: Apr 09, 2022

PharmAla Biotech adds David Purcell as Director of Sales

Posted: Mar 14, 2022

PharmAla Biotech contracts with InterVivo Solutions to validate novel MDMA analogs

Posted: Mar 07, 2022

Global Wellness Strategies Signs MDMA Supply Agreement with PharmAla Biotech

Posted: Feb 10, 2022

PharmAla Biotech initiates research at the University of Arkansas for Medical Sciences

Posted: Jan 17, 2022

PharmAla Biotech Announces Listing on the Canadian Securities Exchange

Posted: Jan 10, 2022

Search Releases

Type keywords to filter the list of press releases:

Media Inquiries

Nicholas Kadysh, CEO